SHL Telemedicine Ltd. Files 20-F/A Amendment

TL;DR

SHL Telemedicine filed a 20-F/A amendment for 2023, showing no major past-due receivables and detailing goodwill impairment calculations.

AI Summary

SHL Telemedicine Ltd. filed an amendment (20-F/A) on July 24, 2024, for the fiscal year ending December 31, 2023. The filing details financial information, including billed accounts receivable terms of 30-60 days with no material past-due amounts as of December 31, 2023. It also references prime rates and value-in-use calculations for goodwill impairment testing based on five-year cash flow projections.

Why It Matters

This filing provides updated financial details and disclosures for SHL Telemedicine Ltd., which is important for investors and stakeholders to assess the company's financial health and operational status.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and primarily contains financial disclosures and clarifications, not significant new negative events.

Key Numbers

• 30-60 days — Billed Accounts Receivable Terms (Standard payment terms for the company's receivables.)
• 6.25% — Prime Rate (Dec 31, 2023) (Indicates the prevailing interest rate environment at year-end.)
• 4.75% — Prime Rate (Dec 31, 2022) (Provides a comparison for the prime rate trend.)

Key Players & Entities

• SHL Telemedicine Ltd. (company) — Filer of the 20-F/A amendment
• December 31, 2023 (date) — Fiscal year end and reporting date for receivables
• July 24, 2024 (date) — Filing date of the 20-F/A amendment
• 90 YIGAL ALON STREET (address) — Company's business and mailing address
• TEL AVIV ISRAEL (location) — Company's business and mailing address

FAQ

Filing Documents

• zk2431705.htm (20-F/A) — 4927KB
• exhibit_12-1.htm (EX-12.1) — 11KB
• exhibit_12-2.htm (EX-12.2) — 11KB
• exhibit_13-1.htm (EX-13.1) — 5KB
• exhibit_13-2.htm (EX-13.2) — 6KB
• exhibit_15-1.htm (EX-15.1) — 4KB
• image00001.jpg (GRAPHIC) — 46KB
• image0.jpg (GRAPHIC) — 412KB
• image2.jpg (GRAPHIC) — 5KB
• image3.jpg (GRAPHIC) — 4KB
• image00004.jpg (GRAPHIC) — 46KB
• 0001178913-24-002281.txt ( ) — 22269KB
• shlt-20231231.xsd (EX-101.SCH) — 133KB
• shlt-20231231_cal.xml (EX-101.CAL) — 73KB
• shlt-20231231_def.xml (EX-101.DEF) — 389KB
• shlt-20231231_lab.xml (EX-101.LAB) — 1421KB
• shlt-20231231_pre.xml (EX-101.PRE) — 661KB
• zk2431705_htm.xml (XML) — 5495KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b2 of the Exchange Act). Yes No EXPLANATORY NOTE This Amendment No. 1 on Form 20-F/A (this " Amendment ") is being filed by SHL Telemedicine Ltd. to amend its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, originally filed with the U.S. Securities Exchange Commission (the " SEC ") on April 18, 2024 (the " Original Filing "). All references in this Amendment to the "Annual Report on Form 20-F" shall be deemed to refer to this Amendment. SHL Telemedicine Ltd. is filing this Amendment solely to (a) amend the disclosure set forth in Item 15(a) of the Original Filing regarding management's conclusions regarding the effectiveness of disclosure controls and procedures; (b) amend the disclosure set forth in Item 15(b) to include Management's Report on Internal Control over Financial Reporting; (c) amend the disclosure set forth in Item 15(d) related to changes in internal control over financial reporting; (d) include new and updated Section 302 Certifications as Exhibits 12.1 and 12.2 containing corresponding amendments to the language set forth in paragraph 4 thereof with respect to internal control over financial reporting; (e) include new and updated Section 906 Certifications furnished as Exhibits 13.1 and 13.2, which inadvertently referred to the incorrect fiscal year in the Original Filing; and (f) correct typographical errors in the Exhibit Index contained in the Original Filing. Although this Amendment includes all of the Parts, Items, information, disclosures and Exhibits contained in the Original Filing as required by the SEC's rules, it speaks as of the original filing date of the Original Filing and does not, and does not purport to, amend, modify, update, restate or change in any way any of such Parts, Items, information, disclosure or Exhibits contained in the Original Fling, including the previo

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 67 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 70 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 72 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 72 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 72 ITEM 16. [RESERVED] 74 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 74 ITEM 16B. CODE OF ETHICS 74 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 74 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 75 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 75 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFIED ACCOUNTANT 75 ITEM 16G. CORPORATE GOVERNANCE 75 ITEM 16H. MINE SAFETY DISCLOSURE 75 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 75 ITEM 16J. INSIDER TRADING POLICIES 75 ITEM 16K. CYBERSECURITY 75 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 76 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 76 ITEM 19. EXHIBITS 77 CONVENTIONS USED IN THIS ANNUAL REPORT In this Annual Report on Form 20F, unless the context otherwise requires: "SHL," "the company," "us," "we" and "our" refer to SHL Telemedicine Ltd. and its subsidiaries; "SHL Telemedicine" refers only to SHL Telemedicine Ltd., and "Mediton" refers to the Mediton Group, in which we acquired a 70% interest on August 31, 2021. Additionally, in this Annual Report: "CHF" and "Swiss francs" refer to the legal currency of Switzerland; "NIS" refers to New Israeli Shekels, the legal currency of the State of Israel; "

RISK FACTORS

RISK FACTORS The realization of one or more of the events described below may have a material adverse effect on our cash flows, results of operations, financial condition, growth prospects and the trading price of our ADSs on Nasdaq and of our ordinary shares on the SIX. You should note that the risks discussed below are not the only risks to which we are exposed. Additional risks, which are not presently known to us or which we currently believe to be immaterial, could likewise result in a material adverse effect on our cash flows, results of operations, financial condition or growth prospects and the trading prices of our ADSs and ordinary shares. This section also contains forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including the risks described below and elsewhere in this Annual Report. The order in which the following risks are presented does not necessarily reflect the likelihood of their occurrence or the relative magnitude of their potential material adverse effects on our cash flows, results of operations, financial condition or growth prospects or the trading prices of our ADSs and ordinary shares. Industry-specific Risks We operate in a highly regulated industry and failure to comply with the complex regulations applicable to us could result in investigations, legal judgments or penalties, which could materially adversely affect our business. Our ability to conduct telehealth services and medical services is subject to a variety of laws and regulatory regimes of the countries and jurisdictions in which we operate and provide our services, including a variety of labor laws, privacy regulations, anti-corruption, anti-competition or financial relationships of healthcare providers with service providers. Such regulatory requirements can vary from country to country and new requirements may be imposed on

View Full Filing

View this 20-F/A filing on SEC EDGAR